We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · March 02, 2020

Talimogene Laherparepvec Treatment Overcomes Locoregional Acquired Resistance to Immune Checkpoint Blockade in Melanoma

Cancer Immunology, Immunotherapy: CII


Additional Info

Cancer Immunology, Immunotherapy: CII
Talimogene Laherparepvec Treatment to Overcome Loco-Regional Acquired Resistance to Immune Checkpoint Blockade in Tumor Stage IIIB-IV M1c Melanoma Patients
Cancer Immunol. Immunother. 2020 Feb 12;[EPub Ahead of Print], A Fröhlich, D Niebel, S Fietz, E Egger, A Buchner, J Sirokay, J Landsberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading